KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash & Current Investments: 2020-2024

Historic Cash & Current Investments for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $597.4 million.

  • Recursion Pharmaceuticals' Cash & Current Investments rose 54.47% to $663.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 billion, marking a year-over-year increase of 43.29%. This contributed to the annual value of $597.4 million for FY2024, which is 51.32% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Cash & Current Investments stood at $597.4 million for FY2024, which was up 51.32% from $394.8 million recorded in FY2023.
  • Recursion Pharmaceuticals' Cash & Current Investments' 5-year high stood at $597.4 million during FY2024, with a 5-year trough of $264.1 million in FY2020.
  • In the last 3 years, Recursion Pharmaceuticals' Cash & Current Investments had a median value of $551.2 million in 2022 and averaged $514.5 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Cash & Current Investments skyrocketed by 95.57% in 2021 and then declined by 28.37% in 2023.
  • Recursion Pharmaceuticals' Cash & Current Investments (Yearly) stood at $264.1 million in 2020, then soared by 95.57% to $516.6 million in 2021, then climbed by 6.70% to $551.2 million in 2022, then dropped by 28.37% to $394.8 million in 2023, then skyrocketed by 51.32% to $597.4 million in 2024.